That ia an excellent downramp sarge well thought out however you forgot to mention the new high proflie board members joining or the new CFO or the international headhunters engaged to find a new CEO or that large Institutional holders have actually been increasing holdings and as far as your comments about the AZD0466 trial well thats already been debunked as nonsense by other holders safety and tolerance is the trials aim then when they increase dosage efficacy studies come into play, stop pushing this lie. Oh and you forgot to men tion Merck ADC trials or Genentech or the Viraleze trial nearing completion in London. So much you choose not too mention just trying to put up another scary downramp as usual. Imo gltah
SPL Price at posting:
37.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)